PEGPH20: Phase II halted

Halozyme halted the open-label, U.S. Phase II Study 202 evaluating PEGPH20 in combination with Abraxane nab-paclitaxel and gemcitabine to treat untreated pancreatic cancer on the recommendation of an independent DMC. Halozyme said it halted enrollment and dosing in the trial as "precautionary actions" while the DMC assesses a possible difference in the thromboembolic event rate between patients treated with PEGPH20 plus Abraxane and gemcitabine and patients treated with Abraxane and gemcitabine alone. Halozyme declined to disclose details, including how many patients have been enrolled in the trial. According to ClinicalTrials.gov, Study 202 is slated to enroll 132 patients. ...